MicroRNAs in Alzheimer’s Disease: Diagnostic Markers or Therapeutic Agents?-Reference-Cited by-同舟云学术

MicroRNAs in Alzheimer’s Disease: Diagnostic Markers or Therapeutic Agents?

Published:2019-06-18 Issue: Volume:10 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Angelucci Francesco,Cechova Katerina,Valis Martin,Kuca Kamil,Zhang Bing,Hort Jakub

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference98 articles.

1. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis;Adams;N. Engl. J. Med.,2018

2. A review of clinical treatment considerations of donepezil in severe Alzheimer’s disease;Adlimoghaddam;CNS Neurosci. Ther.,2018

3. microRNA (miRNA) speciation in Alzheimer’s disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF);Alexandrov;Int. J. Biochem. Mol. Biol.,2012

4. Synaptic dysfunction in Alzheimer’s disease: the effects of amyloid beta on synaptic vesicle dynamics as a novel target for therapeutic intervention;Alifragis;Neural Regen. Res.,2018

5. MiR-124 acts as a target for Alzheimer’s disease by regulating BACE1;An;Oncotarget,2017

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineering supramolecular dynamics of self-assembly and turnover of oncogenic microRNAs to drive their synergistic destruction in tumor models;Biomaterials;2024-09

2. Microglia-targeted inhibition of miR-17 via mannose-coated lipid nanoparticles improves pathology and behavior in a mouse model of Alzheimer’s disease;Brain, Behavior, and Immunity;2024-07

3. Expression profile of miR-214, miR-204, miR-25, miR-15a, IL-33, and plasma level of Malondialdehyde might serve as potential biomarkers for Alzheimer’s disease;2024-06-26

4. miRNA-targeting oligonucleotide constructs with various mechanisms of action as effective inhibitors of carcinogenesis;Biological Products. Prevention, Diagnosis, Treatment;2024-06-04

5. Unraveling the regulatory landscape of Parkinson disease: A molecular symphony of miRNAs, transcription factors, and high-risk genes;Neuroscience Letters;2024-05